The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The current treatment landscape in multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the current treatment landscape for patients with multiple myeloma (MM), providing a detailed insight into the treatment of the disease in Italy. Several treatment approaches and novel combinations of agents are now available for treatment-eligible and ineligible patients, both in the newly diagnosed and relapsed/refractory (R/R) setting. Dr Cerchione is hopeful that, with optimized profiling of patients and sequencing of agents, curative regimens will be available in the future. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Sanofi, GSK, Janssen, BMS-Celgene, Takeda and Karyopharm.
